IBD Research Resource Center

Clinical ID	c3106
Identifier	NL-OMON40895
Trial Title	A study to investigate the safety, tolerability and absorption and elimination of CCX507-B, a new drug for the treatment of patients with inflammatory bowel diseases, in healthy male and female subjects. - CCX507-B SAD/MAD Study.
Trial URL	Visit Original Page

Study Results	No results available
Conditions	Crohn's disease. Inflammatory bowel diseases;10017969
Interventions	Group 1a: 30 mg CCX507-B or placebo once (in fasted state) 30 mg CCX507-B or placebo once daily (in fasted state) 30 mg CCX507-B or placebo twice daily (in fasted state) Group 1b: 30 mg CCX507-B or placebo once (after breakfast) 30 mg CCX507-B or placebo once daily (after breakfast) 30 mg CCX507-B or placebo twice daily (after breakfast and dinner) Group 2a: 60 mg CCX507-B or placebo once (in fasted state) 60 mg CCX507-B or placebo once daily (in fasted state) 60 mg CCX507-B or placebo twice daily (in fasted state) Group 2b: 60 mg CCX507-B or placebo once (after breakfast) 60 mg CCX507-B or placebo once daily (after breakfast) 60 mg CCX507-B or placebo twice daily (after breakfast and dinner) Group 3a: 90 mg CCX507-B or placebo once (in fasted state) 90 mg CCX507-B or placebo once daily (in fasted state) Group 3b: 90 mg CCX507-B or placebo once (after breakfast) 90 mg CCX507-B or placebo once daily (after breakfast)

Sex Requirement	NOT SPECIFIED
Age Requirement	ADULT, ELDER, OLDER_ADULT

Study Type	Interventional
Phase	Not Available